Allergan Plc (AGN) 331.15 $AGN Jim Cramer's 'Ma
Post# of 273254
Posted On: 08/01/2015 2:42:30 AM
Allergan Plc (AGN) 331.15 $AGN
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jul 31, 6:00PM CDT
Cramer takes a closer look at next week's earnings and details how to invest despite the Fed.
FIT: 47.60 (+2.41), TSLA: 266.15 (-0.64), BMRN: 146.27 (+1.71), CLX: 111.94 (-0.09), TAP: 71.14 (+1.07), DIS: 120.00 (-0.03), RL: 125.89 (-1.23), DENN: 11.76 (+0.16), AGN: 331.15 (+2.28), JACK: 95.00 (+0.85), CMG: 742.23 (-1.93), GLD: 104.93 (+0.66), CVS: 112.47 (-0.47), REGN: 553.66 (+6.56)
Market Wrap: Early Gains Don't Last
at The Street - Fri Jul 31, 3:36PM CDT
Hard day for energy shares, better for utilities.
AGN: 331.15 (+2.28), COH: 31.20 (-0.10), CLX: 111.94 (-0.09), HSY: 92.89 (+0.03), OCN: 8.43 (-3.33), DIS: 120.00 (-0.03), CVS: 112.47 (-0.47), VIAB: 57.00 (+0.64), CCE: 51.08 (+5.64), PCLN: 1,243.57 (+21.51), TWX: 88.04 (-0.40), CBS: 53.47 (+0.27), K: 66.17 (+0.08)
Valeant Missed Out On Botox But Hits With Other Buys
at Investor's Business Daily - Fri Jul 31, 3:03PM CDT
If not for acquisitions, Valeant Pharmaceuticals (VRX) would hardly make it on a map of large and fast-growing drug companies. But not only has it earned a spot on such a map, it is all over the map. It sells everything from cancer and neurology...
AGN: 331.15 (+2.28), JNJ: 100.21 (+0.37), VRX: 257.53 (+3.25)
Dr. Reddy's Q1 Earnings & Revenues Rise Y/Y, Offers View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 2:07PM CDT
Dr. Reddy's Laboratories (RDY) reported first-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 58 cents, up 13.7% from the year-ago quarter.
AGN: 331.15 (+2.28), PGNX: 8.66 (+0.20), RDY: 64.35 (+2.35)
Zeltiq Hits New High After Raising Guidance Again
at Investor's Business Daily - Fri Jul 31, 1:06PM CDT
Body-sculpting system maker Zeltiq Aesthetics (ZLTQ) soared to a new high Friday after it reported strong Q2 earnings and raised its outlook late Thursday. Analysts had expected Zeltiq to lose money in the quarter. Instead, it made 3 cents a share,...
AGN: 331.15 (+2.28), ZLTQ: 34.35 (+2.24), KYTH: 74.52 (+0.04)
Teva Secures $33.75 Billion Financing Commitment
Business Wire - Fri Jul 31, 12:22PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it has entered into commitment letters relating to its pending acquisition of Allergan's generic pharmaceuticals business with Bank of America Merrill Lynch, Barclays Bank PLC, BNP Paribas, Citi, Credit Suisse, HSBC, Mizuho Bank, Morgan Stanley Senior Funding, Inc., RBC Capital Markets and Sumitomo Mitsui Banking Corporation.
AGN: 331.15 (+2.28), TEVA: 69.02 (-0.05)
Migraine Pipeline Review, H1 2015: 38 Companies & 56 Drug Profiles
M2 - Fri Jul 31, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wdkbnx/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Alder Biopharmaceuticals Inc. - Allergan, Inc. - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Bristol-Myers Squibb Company - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - D-Pharm Ltd. - Dr. Reddy's Laboratories Limited - Eli Lilly and Company - Heptares Therapeutics Limited - iCeutica, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - NeurAxon, Inc. - Northern Light Pharmaceuticals AB - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Paladin Labs Inc. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/wdkbnx/migraine
BDSI: 8.15 (+0.50), RDHL: 14.82 (-0.08), AMGN: 176.59 (+4.90), LLY: 84.51 (-0.03), ACOR: 34.36 (+0.13), BMY: 65.64 (+1.18), NKTR: 12.61 (+0.28), AGN: 331.15 (+2.28), ALDR: 46.42 (+0.17), CLCD: 8.15 (-0.43), MRK: 58.96 (+0.44), TEVA: 69.02 (-0.05), RVNC: 31.03 (-0.83), POZN: 11.60 (+0.10)
Israel ETFs Surge on Teva Megamerger Deal (revised) - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Fri Jul 31, 8:11AM CDT
The takeover deal of Allergan by Teva has led to a surge in Israel ETFs.
IHE: 181.61 (+1.52), AGN: 331.15 (+2.28), PPH: 74.19 (+0.50), EIS: 55.21 (+0.21), ISRA: 33.76 (+0.03), MYL: 55.99 (-0.36), TEVA: 69.02 (-0.05)
Teva's Q2 Earnings & Revenues Beat Expectations, View Up - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jul 31, 8:03AM CDT
Teva's (TEVA) second quarter results were good with the company beating on both the top-and bottom line.
AGN: 331.15 (+2.28), LGND: 108.26 (+0.48), TEVA: 69.02 (-0.05), AMAG: 63.90 (-0.87), NVS: 103.75 (+0.57)
Six International Leaders Preparing To Report Results
at Investor's Business Daily - Thu Jul 30, 5:23PM CDT
The coming week shows a busy reporting schedule for international stocks. Among those, six of IBD's Top 10 World Stocks are scheduled to deliver results. Dublin, Ireland-based drugmaker (MNK) and (CRTO), an online advertising services agency based in...
AGN: 331.15 (+2.28), MNK: 123.96 (+2.26), NVO: 58.96 (+0.68), JAZZ: 192.24 (+1.86), CRTO: 53.23 (+0.28), ESNT: 29.27 (+0.04)
Allergan Confirms Generic Tyvaso® Patent Challenge
PR Newswire - Thu Jul 30, 7:00AM CDT
Allergan plc (NYSE: AGN) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Treprostinil Inhalation Solution, 0.6 mg/mL, 2.9 mL ampules. Allergan's ANDA product is a generic version of United Therapeutics Corporation's Tyvaso®, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability.
AGN: 331.15 (+2.28), UTHR: 169.36 (+6.57)
Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture to Jointly Develop Botulinum Toxin Market in China
PR Newswire Europe - Wed Jul 29, 10:12PM CDT
Bloomage BioTechnology Corporation Limited ("Bloomage" or "The Company", Stock Code: 00963.HK) announces a strategic cooperation with the South Korean BioTech Company Medytox Inc. ("Medytox", Stock Code: 086900.KS) to establish a joint venture Medybloom to develop and promote Type A Botulinum Toxin ("Botulinum Toxin"
business in China.
AGN: 331.15 (+2.28)
These 4 Foreign Drug Stocks Have Broken Out Recently
at Investor's Business Daily - Wed Jul 29, 5:50PM CDT
Drugmakers and related stocks have had a rough couple of weeks. The Amex Biotechnology Index has slipped a fraction so far this week, after falling nearly 5% from a high the week before. The iShares Nasdaq Biotech Fund (IBB) was little changed for...
AGN: 331.15 (+2.28), SHPG: 266.81 (+4.29), JAZZ: 192.24 (+1.86), IBB: 382.53 (+3.73), TEVA: 69.02 (-0.05), ICLR: 80.80 (-0.06)
Mintz Levin Represents Naurex Inc. in Merger with Allergan PLC
Business Wire - Wed Jul 29, 9:50AM CDT
Attorneys in the Corporate & Securities Section and Life Sciences Practice of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Naurex Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system, in its merger with leading global pharmaceutical company, Allergan PLC. The merger was announced on July 26.
AGN: 331.15 (+2.28)
5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen
at Investor's Business Daily - Tue Jul 28, 7:07PM CDT
Biotechs, generic-drug makers and ethical-drug makers are some of the highest-ranked industry groups among the 197 that IBD tracks, and with recent view-topping earnings reports, FDA approvals and strategic divestments, they're proving their...
MNK: 123.96 (+2.26), AGN: 331.15 (+2.28), GILD: 117.86 (-0.04), JAZZ: 192.24 (+1.86), TEVA: 69.02 (-0.05), SNY: 53.99 (+0.42), REGN: 553.66 (+6.56)
Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:13PM CDT
Allergan (AGN) has agreed to divest global generic pharmaceuticals business to Teva (TEVA) for $40.5 billion.
AGN: 331.15 (+2.28), MYL: 55.99 (-0.36), TEVA: 69.02 (-0.05), AMAG: 63.90 (-0.87)
Aesthetics Insider: Dr. Steven Dayan Goes Inside the New Allergan With CEO Brent Saunders
GlobeNewswire - Tue Jul 28, 3:39PM CDT
The latest edition of Aesthetics Insider with Dr. Steven Dayan has launched from ModernAesthetics.tv and Bryn Mawr Communications III, LCC. In this edition, Dr. Dayan talks with Brent Saunders, CEO of Allergan about Activis' $70 billion merger with Allergan this spring. The newly combined company adopted the Allergan name last month.
AGN: 331.15 (+2.28)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 331.15 (+2.28), BIIB: 318.78 (+1.78), SHPG: 266.81 (+4.29), MYL: 55.99 (-0.36), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), TEVA: 69.02 (-0.05)
Fitch: Teva Remains on Watch Negative on Allergan Generics Acquisition
Business Wire - Tue Jul 28, 1:31PM CDT
According to Fitch Ratings, the ratings of Teva Pharmaceutical Industries Limited (NYSE: TEVA) and its subsidiaries, including the 'BBB+' long-term Issuer Default Rating, remain on Rating Watch Negative, following its announcement that it will acquire the global generics business of Allergan plc (Allergan; NYSE: AGN) for $40.5 billion.
AGN: 331.15 (+2.28), TEVA: 69.02 (-0.05)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jul 31, 6:00PM CDT
Cramer takes a closer look at next week's earnings and details how to invest despite the Fed.
FIT: 47.60 (+2.41), TSLA: 266.15 (-0.64), BMRN: 146.27 (+1.71), CLX: 111.94 (-0.09), TAP: 71.14 (+1.07), DIS: 120.00 (-0.03), RL: 125.89 (-1.23), DENN: 11.76 (+0.16), AGN: 331.15 (+2.28), JACK: 95.00 (+0.85), CMG: 742.23 (-1.93), GLD: 104.93 (+0.66), CVS: 112.47 (-0.47), REGN: 553.66 (+6.56)
Market Wrap: Early Gains Don't Last
at The Street - Fri Jul 31, 3:36PM CDT
Hard day for energy shares, better for utilities.
AGN: 331.15 (+2.28), COH: 31.20 (-0.10), CLX: 111.94 (-0.09), HSY: 92.89 (+0.03), OCN: 8.43 (-3.33), DIS: 120.00 (-0.03), CVS: 112.47 (-0.47), VIAB: 57.00 (+0.64), CCE: 51.08 (+5.64), PCLN: 1,243.57 (+21.51), TWX: 88.04 (-0.40), CBS: 53.47 (+0.27), K: 66.17 (+0.08)
Valeant Missed Out On Botox But Hits With Other Buys
at Investor's Business Daily - Fri Jul 31, 3:03PM CDT
If not for acquisitions, Valeant Pharmaceuticals (VRX) would hardly make it on a map of large and fast-growing drug companies. But not only has it earned a spot on such a map, it is all over the map. It sells everything from cancer and neurology...
AGN: 331.15 (+2.28), JNJ: 100.21 (+0.37), VRX: 257.53 (+3.25)
Dr. Reddy's Q1 Earnings & Revenues Rise Y/Y, Offers View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 2:07PM CDT
Dr. Reddy's Laboratories (RDY) reported first-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 58 cents, up 13.7% from the year-ago quarter.
AGN: 331.15 (+2.28), PGNX: 8.66 (+0.20), RDY: 64.35 (+2.35)
Zeltiq Hits New High After Raising Guidance Again
at Investor's Business Daily - Fri Jul 31, 1:06PM CDT
Body-sculpting system maker Zeltiq Aesthetics (ZLTQ) soared to a new high Friday after it reported strong Q2 earnings and raised its outlook late Thursday. Analysts had expected Zeltiq to lose money in the quarter. Instead, it made 3 cents a share,...
AGN: 331.15 (+2.28), ZLTQ: 34.35 (+2.24), KYTH: 74.52 (+0.04)
Teva Secures $33.75 Billion Financing Commitment
Business Wire - Fri Jul 31, 12:22PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it has entered into commitment letters relating to its pending acquisition of Allergan's generic pharmaceuticals business with Bank of America Merrill Lynch, Barclays Bank PLC, BNP Paribas, Citi, Credit Suisse, HSBC, Mizuho Bank, Morgan Stanley Senior Funding, Inc., RBC Capital Markets and Sumitomo Mitsui Banking Corporation.
AGN: 331.15 (+2.28), TEVA: 69.02 (-0.05)
Migraine Pipeline Review, H1 2015: 38 Companies & 56 Drug Profiles
M2 - Fri Jul 31, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wdkbnx/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Alder Biopharmaceuticals Inc. - Allergan, Inc. - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Bristol-Myers Squibb Company - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - D-Pharm Ltd. - Dr. Reddy's Laboratories Limited - Eli Lilly and Company - Heptares Therapeutics Limited - iCeutica, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - NeurAxon, Inc. - Northern Light Pharmaceuticals AB - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Paladin Labs Inc. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/wdkbnx/migraine
BDSI: 8.15 (+0.50), RDHL: 14.82 (-0.08), AMGN: 176.59 (+4.90), LLY: 84.51 (-0.03), ACOR: 34.36 (+0.13), BMY: 65.64 (+1.18), NKTR: 12.61 (+0.28), AGN: 331.15 (+2.28), ALDR: 46.42 (+0.17), CLCD: 8.15 (-0.43), MRK: 58.96 (+0.44), TEVA: 69.02 (-0.05), RVNC: 31.03 (-0.83), POZN: 11.60 (+0.10)
Israel ETFs Surge on Teva Megamerger Deal (revised) - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Fri Jul 31, 8:11AM CDT
The takeover deal of Allergan by Teva has led to a surge in Israel ETFs.
IHE: 181.61 (+1.52), AGN: 331.15 (+2.28), PPH: 74.19 (+0.50), EIS: 55.21 (+0.21), ISRA: 33.76 (+0.03), MYL: 55.99 (-0.36), TEVA: 69.02 (-0.05)
Teva's Q2 Earnings & Revenues Beat Expectations, View Up - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jul 31, 8:03AM CDT
Teva's (TEVA) second quarter results were good with the company beating on both the top-and bottom line.
AGN: 331.15 (+2.28), LGND: 108.26 (+0.48), TEVA: 69.02 (-0.05), AMAG: 63.90 (-0.87), NVS: 103.75 (+0.57)
Six International Leaders Preparing To Report Results
at Investor's Business Daily - Thu Jul 30, 5:23PM CDT
The coming week shows a busy reporting schedule for international stocks. Among those, six of IBD's Top 10 World Stocks are scheduled to deliver results. Dublin, Ireland-based drugmaker (MNK) and (CRTO), an online advertising services agency based in...
AGN: 331.15 (+2.28), MNK: 123.96 (+2.26), NVO: 58.96 (+0.68), JAZZ: 192.24 (+1.86), CRTO: 53.23 (+0.28), ESNT: 29.27 (+0.04)
Allergan Confirms Generic Tyvaso® Patent Challenge
PR Newswire - Thu Jul 30, 7:00AM CDT
Allergan plc (NYSE: AGN) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Treprostinil Inhalation Solution, 0.6 mg/mL, 2.9 mL ampules. Allergan's ANDA product is a generic version of United Therapeutics Corporation's Tyvaso®, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability.
AGN: 331.15 (+2.28), UTHR: 169.36 (+6.57)
Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture to Jointly Develop Botulinum Toxin Market in China
PR Newswire Europe - Wed Jul 29, 10:12PM CDT
Bloomage BioTechnology Corporation Limited ("Bloomage" or "The Company", Stock Code: 00963.HK) announces a strategic cooperation with the South Korean BioTech Company Medytox Inc. ("Medytox", Stock Code: 086900.KS) to establish a joint venture Medybloom to develop and promote Type A Botulinum Toxin ("Botulinum Toxin"
business in China. AGN: 331.15 (+2.28)
These 4 Foreign Drug Stocks Have Broken Out Recently
at Investor's Business Daily - Wed Jul 29, 5:50PM CDT
Drugmakers and related stocks have had a rough couple of weeks. The Amex Biotechnology Index has slipped a fraction so far this week, after falling nearly 5% from a high the week before. The iShares Nasdaq Biotech Fund (IBB) was little changed for...
AGN: 331.15 (+2.28), SHPG: 266.81 (+4.29), JAZZ: 192.24 (+1.86), IBB: 382.53 (+3.73), TEVA: 69.02 (-0.05), ICLR: 80.80 (-0.06)
Mintz Levin Represents Naurex Inc. in Merger with Allergan PLC
Business Wire - Wed Jul 29, 9:50AM CDT
Attorneys in the Corporate & Securities Section and Life Sciences Practice of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Naurex Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system, in its merger with leading global pharmaceutical company, Allergan PLC. The merger was announced on July 26.
AGN: 331.15 (+2.28)
5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen
at Investor's Business Daily - Tue Jul 28, 7:07PM CDT
Biotechs, generic-drug makers and ethical-drug makers are some of the highest-ranked industry groups among the 197 that IBD tracks, and with recent view-topping earnings reports, FDA approvals and strategic divestments, they're proving their...
MNK: 123.96 (+2.26), AGN: 331.15 (+2.28), GILD: 117.86 (-0.04), JAZZ: 192.24 (+1.86), TEVA: 69.02 (-0.05), SNY: 53.99 (+0.42), REGN: 553.66 (+6.56)
Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:13PM CDT
Allergan (AGN) has agreed to divest global generic pharmaceuticals business to Teva (TEVA) for $40.5 billion.
AGN: 331.15 (+2.28), MYL: 55.99 (-0.36), TEVA: 69.02 (-0.05), AMAG: 63.90 (-0.87)
Aesthetics Insider: Dr. Steven Dayan Goes Inside the New Allergan With CEO Brent Saunders
GlobeNewswire - Tue Jul 28, 3:39PM CDT
The latest edition of Aesthetics Insider with Dr. Steven Dayan has launched from ModernAesthetics.tv and Bryn Mawr Communications III, LCC. In this edition, Dr. Dayan talks with Brent Saunders, CEO of Allergan about Activis' $70 billion merger with Allergan this spring. The newly combined company adopted the Allergan name last month.
AGN: 331.15 (+2.28)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 331.15 (+2.28), BIIB: 318.78 (+1.78), SHPG: 266.81 (+4.29), MYL: 55.99 (-0.36), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), TEVA: 69.02 (-0.05)
Fitch: Teva Remains on Watch Negative on Allergan Generics Acquisition
Business Wire - Tue Jul 28, 1:31PM CDT
According to Fitch Ratings, the ratings of Teva Pharmaceutical Industries Limited (NYSE: TEVA) and its subsidiaries, including the 'BBB+' long-term Issuer Default Rating, remain on Rating Watch Negative, following its announcement that it will acquire the global generics business of Allergan plc (Allergan; NYSE: AGN) for $40.5 billion.
AGN: 331.15 (+2.28), TEVA: 69.02 (-0.05)
(0)
(0)Scroll down for more posts ▼